Soleno Therapeutics (NASDAQ: SLNO) is one of 82 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its rivals? We will compare Soleno Therapeutics to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

65.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 69.8% of Soleno Therapeutics shares are held by insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares Soleno Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soleno Therapeutics -1,389.76% -54.11% -46.95%
Soleno Therapeutics Competitors -432.05% -52.35% -16.67%

Valuation and Earnings

This table compares Soleno Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Soleno Therapeutics $1.45 million -$12.06 million -1.01
Soleno Therapeutics Competitors $975.11 million $120.37 million 223.15

Soleno Therapeutics’ rivals have higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings for Soleno Therapeutics and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics 0 0 1 0 3.00
Soleno Therapeutics Competitors 218 1268 2747 97 2.63

Soleno Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 396.89%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.49%. Given Soleno Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than its rivals.

Volatility and Risk

Soleno Therapeutics has a beta of 5.99, suggesting that its stock price is 499% more volatile than the S&P 500. Comparatively, Soleno Therapeutics’ rivals have a beta of 0.95, suggesting that their average stock price is 5% less volatile than the S&P 500.


Soleno Therapeutics rivals beat Soleno Therapeutics on 7 of the 12 factors compared.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with's FREE daily email newsletter.